The diagnosis of Alzheimer disease (AD) dementia is based primarily on the clinical history and examination, but advances in understanding the pathophysiology of AD have led to new diagnostic methods. When used appropriately, the tests can provide strong positive or negative evidence AD dementia. This article described which patients may benefit from additional testing using Cerebrospinal Fluid (CSF) biomarkers, amyloid imaging, quantitative structural magnetic resonance imaging (MRI), and fluoro-deoxyglucose positron emission tomography (FDG-PET).
|Number of pages||5|
|State||Published - Jan 1 2013|